Oct 27, 2026 · 3 min listen · Last updated October 27, 2026
From storyflo. This is your daily audio brief. Hi, it's Chloe. October 27th. Ten in science — the one that made me re-read the abstract is at the top. Let's get into it. First, from MD REPORTS. Is it the lipid nanoparticles?.
Listen · storyflo · science
Daily Science Brief · October 27th
0:00-3:04
Pick your daily storyteller
Subscribe to match with Theo, Jessica, Chloe, Mason, Brock — your voice, every brief.
Audio pre-rendered by Storyflo · cached + delivered from the edge
Is it the lipid nanoparticles?
A recent study from Australia has highlighted a notable difference between the lipid nanoparticles used in Pfizer’s and Moderna’s Covid vaccines. While both vaccines utilize these tiny fat particles to transport mRNA into cells, researchers found that the primary lipid in Pfizer’s vaccine stays in the bloodstream for a significantly longer time compared to Moderna’s.
This research shifts the focus from just the mRNA and the spike protein it creates, which have been the main subjects of discussion for years. It suggests that the lipid nanoparticles themselves might play a more crucial role in vaccine responses than previously thought. Since these lipid particles can trigger inflammatory reactions even without the mRNA, this raises important questions about whether their prolonged presence in the body could be linked to some vaccine-related injuries. It’s a reminder that the components of vaccines are complex, and understanding them fully is essential for safety and efficacy.
One Dose of Experimental Antibody Kept HIV-Like Virus in Remission For 4 Years in a Monkey
Researchers have made some intriguing progress in the fight against HIV by testing an experimental antibody in infant monkeys. This study, published in Nature Microbiology, involved giving a single dose of the antibody alongside early antiviral treatment to newborn rhesus macaques infected with a virus similar to HIV, called SIV. The results were promising: one monkey maintained undetectable virus levels for four years after stopping medication, while others showed prolonged remission.
The antibody targets immune cells with a specific surface protein, CCR5, which HIV uses to infect cells. By directing T cells to attack these CCR5-expressing cells, the researchers aimed to reduce the viral reservoirs where the virus can hide. While the study was small and focused on young monkeys, it suggests that this approach could potentially lead to a more effective way to manage or even cure HIV, especially if treatment starts early.
However, it's important to note that this research is still in its early stages. The approach hasn't been tested in humans yet, and there are questions about its effectiveness in adults or those with chronic infections. Plus, the antibody also targets uninfected immune cells, so further studies are needed to understand any potential impacts on the immune system. Overall, it's a hopeful step forward, but there's still a long way to go before we can draw any definitive conclusions.
27 exoplanet targets for the world's first private space telescope
The Lazuli Space Telescope will be the first private space telescope. It's the brainchild of Eric Schmidt, Google's former CEO. It will have a 3-meter mirror (9.8 feet), larger than Hubble's 2.4-meter mirror (7.9 feet), and will be launched by 2029.
False lingzhi unmasked: Scientists crack the 245-year mystery behind a medicinal mushroom mix-up
In a new study published today in Plants, People, Planet, scientists from the Royal Botanic Gardens, Kew, and their international collaborators clarify the distinction between Ganoderma lucidum, a European bracket fungus described in 1781, and Ganoderma lingzhi, the East Asian species widely associated with medicinal lingzhi or reishi.
Success! IBM Hits 99% Accuracy Transferring Quantum Information Between Chips
Prototype quantum computers already exist, but if we're to truly realize their full potential, they need to be significantly scaled up and stabilized – and a team of researchers from IBM just announced an important step toward this goal. The upgrade concerns the long-distance couplers (L-couplers) that connect qubits together. Qubits sit at the heart of quantum computers, and unlike the conventional bits that underpin classical computing, they're not restricted to a binary state of 1 or 0.